Methods
ADVERSE EVENTS
From July 2018 to January 2020, a prospective randomized controlled trial was conducted in analgesia management after RPD for “3‐in‐1” procedure surgery. The 40 patients in the experimental group received ACB (0.3% ropivacaine 30 mL) + GA, while the 38 patients in the control group received SGA. Patients in both groups received “3‐in‐1” procedure surgery, standardized anesthesia, and analgesia during hospitalization. The outcomes included the visual analog scale (VAS), quadriceps strength, Inpatient Satisfaction Questionnaire (IPSQ), Lysholm scores, and Kujala scores. Total rescue analgesic consumption and adverse events were also recorded. One‐way analysis of variance (ANOVA) was used to compare continuous variables between groups and chi‐square or Fisher's exact tests were used to compare count data. Nonparametric Kruskal–Wallis H tests evaluated ranked data.